Immuneering Corporation (IMRX)
| Market Cap | 665.34M |
| Revenue (ttm) | 2.58M |
| Net Income (ttm) | -20.07M |
| Shares Out | 24.39M |
| EPS (ttm) | -0.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 165,867 |
| Open | 25.14 |
| Previous Close | 25.27 |
| Day's Range | 23.46 - 27.41 |
| 52-Week Range | 16.06 - 33.99 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 43.67 (+60.1%) |
| Est. Earnings Date | Nov 15, 2021 |
About IMRX
Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying our deep knowledge of translational bioinformatics to every stage of the drug development process. We have more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, we developed a disease-agnostic platform that enables us to utilize human ...
Financial Performance
In 2020, Immuneering's revenue was $2.31 million, an increase of 20.41% compared to the previous year's $1.92 million. Losses were -$17.04 million, 121.0% more than in 2019.
Financial StatementsNews
Immuneering Announces Inclusion in the Russell 2000® Index
CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that ...
5 Stocks With High Insider Buys Over Past 2 Months
According to the Insider Cluster Buys page, a Premium feature of GuruFocus, five stocks with high insider buys over the past two months are Orange County Bancorp Inc. ( OBT , Financial), FS KKR Capital ...
Immuneering Reports Second Quarter 2021 Financial Results and Provides Business Updates
Recently completed upsized initial public offering raising $129.4 million in gross proceeds, providing runway into 2024
Immuneering to Participate in September Investor Conferences
CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that ...
Immuneering Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to ...
CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that a...
Oncology-Focused Biotech Immuneering Jumps To Wall Street With $112M IPO
Immuneering Corp (NASDAQ: IMRX) has kept a relatively low profile since launching with $17 million back in 2019. That is until it landed another $62 million and recruited Jefferies analyst Biren Amin as...
Immuneering Announces Pricing of Upsized Initial Public Offering
Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of...
Immuneering IPO Registration Document (S-1)
Immuneering Corporation has filed to go public with an IPO on the NASDAQ.